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AUGUSTUS Trial: In Patients With Atrial 
Fibrillation (AF) and a Recent Acute Coronary 
Syndrome (ACS) or PCI Treated With a P2Y12 
Inhibitor, an Antithrombotic Regimen Including 
Apixaban, Without Aspirin, Resulted in Less 
Bleeding and Fewer Hospitalizations Without 
Significant Differences in the Incidence of Ischemic 
Events Than Regimens that Included a Vitamin K 
Antagonist (VKA), Aspirin, or Both  
Among 4614 AF patients with ACS or PCI, major or 
clinically relevant nonmajor bleeding was noted in 10.5% 
of the patients receiving apixaban, as compared with 
14.7% of those receiving a VKA (hazard ratio-HR, 0.69; 
P<0.001 for both noninferiority and superiority), and in 
16.1% of the patients receiving aspirin, as compared with 
9.0% of those receiving placebo (HR, 1.89; P<0.001). 
Patients in the apixaban group had a lower incidence of 
death or hospitalization than those in the VKA group 
(23.5% vs. 27.4%; HR, 0.83; P=0.002) and a similar 
incidence of ischemic events. Patients in the aspirin group 
had an incidence of death or hospitalization and of 
ischemic events that was similar to that in the placebo 
group (Lopes RD et al, N Engl J Med 2019; 380:1509-24).  
 
COACT Trial: Among Patients Successfully 
Resuscitated After Out-Of-Hospital Cardiac Arrest 
with no Signs of STEMI, a Strategy of Immediate 
Angiography Was Not Found to be Better Than a 
Strategy of Delayed Angiography With Respect to 
Overall Survival at 90 Days  
At 90 days, 176 of 273 patients (64.5%) in the 
immediate angiography group and 178 of 265 patients 
(67.2%) in the delayed (delayed until after neurologic 
recovery) angiography group were alive (odds ratio, 0.89; 
P=NS). The median time to target temperature was 5.4 h 
in the immediate angiography group and 4.7 h in the 
delayed angiography group. No significant differences 
between the groups were found in the remaining secondary 
end points (Lemkers JS et al, N Engl J Med 2019; 
380:1397-1407).  
 
ANNEXA-4: In Patients With Acute Major Bleeding 
Associated With Use of a Factor Xa Inhibitor, 
Treatment With Andexanet Markedly Reduced Anti–
Factor Xa Activity, and 82% of Patients Had Excellent 
or Good Hemostatic Efficacy at 12 Hours  
Among 352 patients (mean age 77 years, most with 
CV disease) who had acute major bleeding (64% 
intracranial and 26% gastrointestinal) within 18 h after a 
factor Xa inhibitor and received a bolus of andexanet, 
followed by a 2-hour infusion, in patients who had 
received apixaban, the median anti–factor Xa activity 
decreased from 149.7 ng/ml at baseline to 11.1 ng/ml after 
the andexanet bolus (92% reduction); in patients who had 
received rivaroxaban, the median value decreased from 
211.8 ng/ml to 14.2 ng/ml (92% reduction). Excellent or 
good hemostasis occurred in 204 of 249 patients (82%) 
who could be evaluated. Within 30 days, death occurred in 
49 patients (14%) and a thrombotic event in 34 (10%). 
Reduction in anti–factor Xa activity was not predictive of 
hemostatic efficacy overall but was modestly predictive in 
patients with intracranial hemorrhage (Connolly SJ et al, N 
Engl J Med 2019; 380:1326-35). 
 
Among Patients Undergoing PCI With Baseline LDL-
Cholesterol ≤70mg/dl, Persistent High Residual 
Inflammatory Risk (RIR) (hsCRP >2mg/l) is Frequent 
and is Associated With Increased Risk of MACCE  
Among 3,013 patients undergoing PCI with baseline 
LDL <70 mg/dl, residual inflammatory risk (RIR), defined 
as hsCRP >2mg/l, was persistent low (first low then low 
hsCRP) in 41.7%, attenuated (first high then low hsCRP) 
in 13.7%, increased (first low then high hsCRP) in 11.5%, 
or persistent high (first high then high hsCRP) in 34.1%. 
Overall, there was a stepwise increase in the incidence 
rates of major adverse cardiac and cerebrovascular events 
(MACCE) (death, MI, or stroke), within 1 year of the 
second hsCRP measurement, transitioning from the 
persistent low to the attenuated, increased, and persistent 
high RIR (respectively, 64.4 vs 96.6 vs. 138.0 vs 152.4 per 
1,000 patient-years; p< 0.001). The presence of persistent 
high RIR remained strongly associated with MACCE 
(adjusted hazard ratio: 2.10; p< 0.001) (Guedeney P et al, 
J Am Coll Cardiol 2019;73: 2401-09).  
 
Infusion Needle Radiofrequency (RF) Ablation for 
Refractory Ventricular Arrhythmias: Novel, Effective 
but is it Safe? 
An RF ablation catheter with an extendable/retractable 
27-g needle capable of targeting deep arrhythmia 
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(intramural) substrate was used in 31 patients who failed 
at least one prior catheter ablation procedure for sustained 
ventricular tachycardia (VT; n=26) or nonsustained VA 
with associated LV dysfunction (n=5) (71% nonischemic 
heart disease). After a median of 15 needle lesions/patient, 
ablation abolished at least 1 inducible VT in 19 of 26 VT 
patients (73%), and suppressed ambient arrhythmia in 4 of 
5 nonsustained arrhythmia patients. At the 6-month 
follow-up, 48% of patients were free of recurrent 
arrhythmia and another 19% were improved. Procedure-
related complications included 1 pericardial effusion 
treated with percutaneous drainage and a LV pacing lead 
dislodgement with no deaths (Stevenson WG et al, J Am 
Coll Cardiol 2019;73:1413-25).  
 
YOUNG-MI Registry: Need for More Aggressive 
Lipid-Lowering Therapy in Young Familial 
Hypercholesterolemia (FH) and Non-FH Patients Post-
MI / FH is Present in Nearly 1 of 10 Patients With MI 
at a Young Age / Only Two-Thirds of FH Patients Were 
Discharged on High-Intensity Statin Therapy, and the 
Vast Majority Had Elevated LDL-C at 1 Year  
Among 1,996 patients who experienced an MI at or 
below age 50 years included in the YOUNG-MI registry 
(median age of 45 years; 19% were women, and 54% had 
STEMI), probable/definite FH was present in 180 (9%) of 
whom 42.8% were not on statins prior to their MI. Of the 
1,966 patients surviving until hospital discharge, 89.4% of 
FH patients and 89.9% of non-FH patients were discharged 
on statin therapy (p = 0.82). Among FH patients, 63.3% 
were discharged on high-intensity statin compared with 
48.4% for non-FH patients (p < 0.001). At 1-year follow-
up, the percent reduction in LDL-C among FH patients 
was −44.4% compared with −34.5% (p = 0.006) in non-
FH patients. The proportion of patients with LDL-
C ≥70 mg/dl was higher among FH patients (82.2%) 
compared with non-FH patients (64.5%; p< 0.001) (Singh 
A et al, J Am Coll Cardiol 2019; 73:2439-50).  
 
Among Non-LBBB CRT-D–Eligible Patients, CRT-D 
Implantation Was Associated With Better Outcomes 
Compared With ICD Alone Specifically in Non-
Specific Intraventricular Conduction Delay (IVCD) 
Patients With a QRS Duration of ≥150 ms  
In 11,505 non-LBBB CRT-eligible patients, after 
multivariable adjustment, among patients with RBBB, 
CRT-D was not associated with better outcomes, 
compared with ICD alone, regardless of QRS duration. 
Among patients with IVCD and a QRS ≥150 ms, CRT-D 
was associated with decreased mortality at 3 years 
compared with ICD alone (HR: 0.602; p=0.0071). Among 
5,954 CRT-D–implanted patients, after multivariable 
adjustment IVCD compared with RBBB was associated 
with lower mortality at 3 years in those with a QRS 
duration of ≥150 ms (HR: 0.757; p=0.0044) (Kawata H et 
al, J Am Coll Cardiol 2019; 73:3082-99).  
 
MOMENTUM 3: Among Patients With Advanced 
Heart Failure, a Fully Magnetically Levitated 
Centrifugal-Flow Left Ventricular Assist Device 
(LVAD) Was Associated With Less Frequent Need for 
Pump Replacement Than an Axial-Flow Device and 
Fewer Strokes  
Among 1028 enrolled patients, 516 in the centrifugal-
flow pump group and 512 in the axial-flow pump group, 
397 patients (76.9%) in the centrifugal-flow pump group, 
as compared with 332 (64.8%) in the axial-flow pump 
group, remained alive and free of disabling stroke or 
reoperation to replace or remove a malfunctioning device 
at 2 years (relative risk, 0.84; P<0.001 for superiority). 
Pump replacement was less common in the centrifugal-
flow pump group than in the axial-flow pump group (2.3% 
vs. 11.3%]; relative risk, 0.21; P<0.001). The numbers of 
events per patient-year for stroke of any severity, major 
bleeding, and gastrointestinal hemorrhage were lower in 
the centrifugal-flow pump group than in the axial-flow 
pump group (Mehra MR et al, New Engl J Med 2019; 
380:1618-1627).  
 
RACE 7 ACWAS Trial: In Patients Presenting to the 
Emergency Department (ED) With Recent-Onset 
Atrial Fibrillation (AF), a Wait-and-See Approach was 
Noninferior to Early Cardioversion (CV) in Achieving 
a Return to Sinus Rhythm (SR) at 4 Weeks 
 
Patients with hemodynamically stable, recent-onset 
(<36 h), symptomatic AF in the ED were randomly 
assigned to be treated with a wait-and-see approach 
(delayed-CV group, n=212; initial treatment with rate-
control medication only and delayed CV if AF did not 
resolve within 48 h) or early CV (n=215). The presence of 
SR at 4 weeks occurred in 91% in the delayed-CV group 
and in 94% in the early-CV group (P=0.005 for 
noninferiority). In the delayed-CV group, conversion to 
SR within 48 h occurred spontaneously in 150 of 218 
patients (69%) and after delayed CV in 61 patients (28%). 
In the early-CV group, conversion to SR occurred 
spontaneously before the initiation of CV in 36 of 219 
patients (16%) and after CV in 171 patients (78%). Among 
the patients who completed remote monitoring during 4 
weeks of follow-up, a recurrence of AF occurred in 49 of 
164 patients (30%) in the delayed-CV group and in 50 of 
171 (29%) in the early-CV group. Within 4 weeks after 
randomization, cardiovascular complications occurred in 
10 patients and 8 patients, respectively (Pluymaekers 
NAHA et al, N Engl J Med 2019; 380:1499-1508).  
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In Patients With HER2-Positive Breast Cancer 
Treated With Trastuzumab, Both Lisinopril and 
Carvedilol Prevented Cardiotoxicity in Patients 
Receiving Anthracyclines  
Among 468 women (age 51±10.7 years) with breast 
cancer receiving chemotherapy with trastuzumab stratified 
by anthracycline use and then randomized to lisinopril, 
carvedilol or placebo, cardiotoxicity was comparable in the 
3 arms (32% of placebo patients, 29% on carvedilol, and 
30% on lisinopril). For patients receiving anthracyclines, 
the event rates were higher in the placebo group (47%) 
than in the lisinopril (37%) and the carvedilol (31%) 
groups. Cardiotoxicity-free survival was longer on both 
carvedilol (hazard ratio-HR: 0.49; p=0.009) and lisinopril 
(HR: 0.53; p=0.015) than on placebo. In the whole cohort, 
as well as in the anthracycline arm, patients on active 
therapy with either angiotensin-converting enzyme 
inhibitor or beta-blockers experienced fewer interruptions 
in trastuzumab than those on placebo (Guglin M et al et al, 
J Am Coll Cardiol 2019;73:2859-68).  
 
PARTNER 2 Registry: At 3-Year Follow-Up, TAVI for 
Bioprosthetic Aortic Valve Failure Was Associated 
With Favorable Survival, Sustained Improved 
Hemodynamic Status, and Excellent Functional and 
Quality-Of-Life Outcomes  
Among 365 patients having valve-in-valve procedures 
(age 78.9±10.2 years; STS score 9.1±4.7%), at 3 years, all-
cause mortality was 32.7%. Aortic valve re-replacement 
was required in 1.9%. Mean transaortic gradient was 35 
mmHg at baseline, decreasing to 17.8 mmHg at 30-days 
and 16.6 mmHg at 3-years. Baseline effective orifice area 
was 0.93 cm2, increasing to 1.13 and 1.15 cm2 at 30 days 
and 3 years, respectively. Moderate to severe aortic 
regurgitation was reduced from 45.1% at pre-TAVI 
baseline to 2.5% at 3 years. Moderate or severe mitral and 
tricuspid regurgitation also decreased. Baseline left 
ventricular (LV) ejection fraction was 50.7%, increasing to 
54.7% at 3 years (p< 0.0001), while LV mass index was 
136.4 g/m2, decreasing to 109.1 g/m2 at 3 years (p< 
0.0001). NYHA functional class improved, with 90.4% in 
class III or IV at baseline and 14.1% at 3 years (p< 0.0001), 
and quality of life score increased (43.1 to 73.1; p< 0.0001) 
(Webb JG et al, J Am Coll Cardiol 2019;73: 2647-55).  
 
Delayed AV Block: An Underappreciated 
Complication of TAVI Among Patients Without Pre-
Procedure Pacing Devices, Occurring at Rates Similar 
to In-Hospital, Acute Post-TAVI AV Block / RBBB is a 
Risk Factor 
Among 150 consecutive TAVI patients without a 
prior pacing device, 18 (12%) developed high-degree 
AV block necessitating permanent pacemaker <2 
days post-TAVI, 1 died pre-discharge, and 13 
declined ambulatory event monitoring (AEM); 118 
had 30-day AEM data. Delayed AV block occurred in 
12 (10% of AEM patients, 8% of total cohort) a 
median of 6 days (range 3 to 24 days) post-TAVI. 
Delayed AV block patients were more likely to have 
hypertension and right bundle branch block (RBBB). 
Sensitivity and specificity of RBBB in predicting AV 
block was 27% and 94%, respectively (Ream K et al, J 
Am Coll Cardiol 2019;73:2538–47).  
 
Meta-Analysis: Sham-Controlled Randomized Trials 
of Renal Denervation (RD) in Patients With 
Hypertension Indicate Significantly Reduced Blood 
Pressure (BP) Compared with Sham Control 
 
In a meta-analysis of 977 patients from 6 trials, the 
reduction in 24-h ambulatory systolic BP was significantly 
greater for patients treated with RD than sham procedure 
(mean difference −3.65 mmHg, p<0.001). Compared with 
sham, RD was also associated with a significant decrease 
in daytime systolic BP, office systolic BP, 24-h ambulatory 
diastolic BP, daytime ambulatory diastolic BP, and office 
diastolic BP (p< 0.05). Compared with first-generation 
trials, a significantly greater reduction in daytime BP was 
observed with RD in second-generation trials (6.12 mmHg 
vs. 2.14 mmHg; p interaction=0.04); however, this 
interaction was not significant for 24-h ambulatory systolic 
BP (Sardar P et al J Am Coll Cardiol 2018;72:1633–42).  
 
The 5-Year Incidence of Infective Endocarditis (IE) 
Following TAVI Was 5.8% and not Significantly 
Different Than the Incidence Following Surgical AVR 
 
Among 2,632 patients undergoing TAVI and 
3,777 patients undergoing isolated surgical AVR, 
over a mean of 3.6 years, 115 patients (4.4%) with 
TAVI and 186 patients (4.9%) with VR were admitted 
with IE. The median time from procedure to IE 
hospitalization was 352 days in TAVI and 625 days 
in AVR. The crude incidence rates of IE were 1.6 and 
1.2 events per 100 person-years in TAVI and AVR 
patients, respectively. The cumulative 1-year risk of 
IE was 2.3% and 1.8% in TAVI and AVR patients, 
respectively. Correspondingly, the cumulative 5-year 
risk of IE was 5.8% in TAVI and 5.1% in AVR. In 
multivariable analysis, TAVI was not associated with 
a statistically significant different risk of IE compared 
with AVR (hazard ratio: 1.12) (Butt JH et al, J Am Coll 
Cardiol 2018;72:1646–55).  
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Benefits of Eating Breakfast in Promoting 
Cardiovascular (CV) Health  
 
In a prospective cohort study of 6,550 adults 40-75 
years of age (mean age 53.2 years; 48.0% male), 5.1% 
never had breakfast, 10.9% rarely had breakfast, 25% had 
breakfast some days, and 59% had breakfast every day. 
During 112,148 person-years of follow-up, 2,318 deaths 
occurred including 619 deaths from CV disease. After 
adjustment for age, sex, race/ethnicity, socioeconomic 
status, dietary and lifestyle factors, body mass index, and 
CV risk factors, participants who never had breakfast 
compared with those having breakfast everyday had 
hazard ratios of 1.87 for CV mortality and 1.19 for all-
cause mortality. The authors concluded that skipping 
breakfast was associated with a significantly increased risk 
of mortality from CV disease (Rong S et al, J Am Coll 
Cardiol 2018;72:2025-32).  
 
Lung Disease is Associated With Cardiovascular (CV) 
Diseases, Particularly Ischemic Heart Disease (IHD) 
and Heart Failure (HF), Contributing to All-Cause 
Mortality / However, Patients With Lung Disease are 
Less Likely to Get Revascularized  
Among 31,646 COPD, 60,424 asthma, and 1,662 
interstitial lung disease (ILD) patients compared with 
controls (n=158230, n=302120, and n=8310, 
respectively), COPD was independently associated with 
IHD, HF, atrial fibrillation, and peripheral vascular 
disease, all of which were associated with all-cause 
mortality (e.g., odds ratio for the association of COPD with 
HF: 2.18; hazard ratio for the contribution of HF to 
mortality in COPD: 1.65). Asthma was independently 
associated with IHD, and multiple CV diseases contributed 
to mortality (e.g., HF hazard ratio: 1.81). ILD was 
independently associated with IHD and HF, both of which 
were associated with mortality. Patients with lung disease 
were less likely to receive coronary revascularization. 
(Carter P et al, J Am Coll Cardiol 2018;72:2166-77). 
 
DECISION-CTO Trial: Chronic Total Occlusion 
(CTO)-PCI Was Feasible With High Success Rates, but 
There was no Difference in Major Adverse 
Cardiovascular Events (MACE) 
Among 834 patients randomly assigned to the CTO-
PCI (n=417) or no CTO-PCI strategy (n=398; 78 or 19.6% 
crossed over to receive staged CTO-PCI within 3 days of 
randomization), the overall CTO-PCI success rate was 
90.6%. Serious nonfatal complications associated with 
CTO-PCI occurred in 3 patients (1 stroke, 1 cardiac 
tamponade, and 1 patient with recurrent episodes of 
ventricular tachyarrhythmia induced by intracoronary 
thrombus). About half of the patients in each group 
underwent PCI for an average of 1.3 non-CTO lesions, 
resulting in a comparable residual SYNTAX score 
confined to non-CTO vessels. During a median of 4 years, 
there was no significant difference between the CTO-PCI 
and the no CTO-PCI strategies in the incidence of the 
primary end point (death, MI, stroke, revascularization) 
(22.3% vs 22.4%). Both CTO-PCI and no CTO-PCI 
strategy were associated with significant improvements 
but without between-group differences in disease-specific 
health status that was sustained through 3 years (Lee SW 
et al, Circulation 2019;139:1674–83).  
 
Focal atrial tachycardia (FAT) ablation: Highly 
successful with conventional mapping 
 
Conventional mapping-guided catheter ablation in 63 
FAT patients (aged 42.4±17.3 years; 14 with incessant 
tachycardia and 12 with tachycardiomyopathy - TCM), 
was successful in 61 (96.8%), applied for single foci in 59 
(93.7%) and two foci in 4 patients, right (n = 46) or left 
sided (n = 17). The earliest atrial activation time was 
41.3 ± 16.2 ms. Fluoroscopy time was 27.3±18.7 min, and 
procedure lasted 2.6±1.7 h. Complications occurred in 2 
patients (sinus pauses in 1 needing a pacemaker and a large 
inguinal hematoma in 1). Over 29.0±22.9 months, 4 
patients (6.5%) had recurrences, of whom 3 were re-
ablated. All patients with TCM showed gradual 
improvement to normalization over 4-6 months (Manolis 
AS & Lazaridis K, J Interv Card Electrophysiol 
2019;55:35–46).  
 
Meta-Analysis: Glucagon-Like Peptide 1 Receptor 
Agonists (GLP1-RA) & Sodium-Glucose Cotransporter 
2 Inhibitors (SGLT2i) Reduce Atherosclerotic MACE 
to a Similar Degree in Patients With Established 
Cardiovascular (CV) Disease, Whereas SGLT2i Have 
a More Marked Effect on Preventing Hospitalization 
for Heart Failure and Progression of Kidney Disease  
Data from 8 trials and 77,242 patients, 42,920 (55.6%) 
in GLP1-RA trials, and 34,322 (44.4%) in SGLT2i trials, 
showed that both drug classes reduced MACE in a similar 
magnitude with GLP1-RA reducing the risk by 12% 
(hazard ratio -HR, 0.88; p<0.001) and SGLT2i by 11% 
(HR, 0.89; p=0.001). For both drug classes, this treatment 
effect was restricted to a 14% reduction in those with 
established atherosclerotic CV disease (HR, 0.86; 
p=0.002), whereas no effect was seen in patients without 
established CV disease (HR, 1.01; 95%; p interaction, 
0.028). SGLT2i reduced hospitalization for heart failure by 
31% (HR, 0.69; p<0.001), whereas GLP1-RA did not have 
a significant effect (HR, 0.93; p=0.20). Both GLP1-RA 
(HR, 0.82; p<0.001) and SGLT2i (HR, 0.62; p<0.001) 
reduced the risk of progression of kidney disease including 
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macroalbuminuria, but only SGLT2i reduced the risk of 
worsening estimated glomerular filtration rate, end-stage 
kidney disease, or renal death (HR, 0.55; p<0.001). 
(Zelniker TA et al, Circulation 2019;139:2022–31).  
 
Health Professionals Studies: Consumption of Sugar-
Sweetened Beverages (SSBs) Increases Mortality 
Primarily Through CVD Mortality with a Graded 
Association with Dose / The Association Between High 
Intake Levels of Artificially-Sweetened Beverages 
(ASBs) and Total and CVD Mortality Observed 
Among Women Requires Further Confirmation  
After adjusting for major diet and lifestyle factors, 
consumption of SSBs was associated with a higher risk of 
total mortality; hazard ratios - HRs across categories 
(<1/mo, 1–4/mo, 2–6/week, 1-<2/d, and ≥2/d) were 1.00 
(reference), 1.01 (0.98, 1.04), 1.06 (1.03, 1.09), 1.14 (1.09, 
1.19), and 1.21 (1.13, 1.28; P trend <0.0001). The 
association was observed for CVD mortality (HR 
comparing extreme categories was 1.31, P trend <0.0001) 
and cancer mortality (1.16, P trend =0.0004). ASBs were 
associated with total and CVD mortality in the highest 
intake category only; pooled HRs across categories were 
1.00 (reference), 0.96, 0.97, 0.98, and 1.04 (P trend = 0.01) 
for total mortality and 1.00 (reference), 0.93, 0.95, 1.02, 
and 1.13 (P trend = 0.02) for CVD mortality. In cohort-
specific analysis, ASBs were associated with mortality in 
NHS (Nurses’ Health Study) but not in HPFS (Health 
Professionals Follow-up Study) (P interaction, 0.01). 
ASBs were not associated with cancer mortality in either 
cohort (Malik VS et al, Circulation 2019;139:2113–25). 
 
Arrhythmic Storm With Recurrent Polymorphic VT in 
Patients With Coronary Disease Responds To 
Quinidine Therapy When Other Antiarrhythmic 
Drugs (Including IV Amiodarone) Fail  
Among 43 patients with polymorphic VT appearing 
within days of an otherwise uncomplicated MI or coronary 
revascularization procedure, the VT events were 
invariably triggered by extrasystoles with short (364±36 
ms) coupling interval. Arrhythmic storms (4–16 events of 
polymorphic VT deteriorating to VF) occurred in 23 (53%) 
patients and remained refractory to conventional 
antiarrhythmic therapy, including IV amiodarone, but 
invariably responded to quinidine therapy. In-hospital 
mortality was 17% for patients with arrhythmic storm. 
Patients treated with quinidine survived to hospital 
discharge. Over 5.6±6 years, 3 (16%) of patients 
discharged without quinidine developed recurrent 
polymorphic VT. There were no recurrent arrhythmias 
during quinidine therapy (Viskin S et al, Circulation 
2019;139:2304–2314).  
 
DECLARE-TIMI 58: Dapagliflozin Reduces Risk of 
MACE and Cardiovascular (CV) Death/ 
Hospitalization for Heart Failure in Patients With 
Type 2 Diabetes Mellitus and Previous MI  
In patients with prior MI (n=3584), dapagliflozin 
reduced the relative risk of MACE by 16% and the 
absolute risk by 2.6% (15.2% vs 17.8%; hazard ratio - HR, 
0.84; P=0.039), whereas there was no effect in patients 
without prior MI (7.1% vs 7.1%), including in patients 
with established CV disease but no history of MI (12.6% 
vs 12.8%). There was a greater benefit for MACE within 2 
years after the last acute event (P for interaction trend= 
0.007). The relative risk reductions in CV death/ hospitali-
zetion for heart failure were similar, but the absolute risk 
reductions tended to be greater: 1.9% (8.6% vs 10.5%; HR, 
0.81; P=0.046) and 0.6% (3.9% vs 4.5%; HR, 0.85; 
P=0.055) in patients with & without prior MI, respectively 
(Furtado RHM et al, Circulation 2019;139:2516–27).  
 
DECLARE-TIMI 58: Dapagliflozin Reduced 
Hospitalization for Heart Failure (HHF) in Patients 
With and Without HFrEF and Reduced CV Death and 
All-Cause Mortality in Patients With HFrEF 
Of 17 160 patients, 671 (3.9%) had HFrEF, 1316 
(7.7%) had HF without known reduced EF, and 15 173 
(88.4%) had no history of HF at baseline. Dapagliflozin 
reduced CV death/HHF more in patients with HFrEF 
(hazard ratio - HR, 0.62) than in those without HFrEF (HR, 
0.88; P for interaction=0.046), in whom the treatment 
effect of dapagliflozin was similar in those with HF 
without known reduced EF (HR, 0.88) and those without 
HF (HR, 0.88). Dapagliflozin reduced HHF both in those 
with (HR, 0.64) and in those without HFrEF (HR, 0.76), it 
reduced CV death only in patients with HFrEF (HR, 0.55) 
(HR, 1.08; p for interaction=0.012). Dapagliflozin reduced 
all-cause mortality in patients with HFrEF (HR, 0.59) but 
not in those without HFrEF (HR, 0.97; p for interaction= 
0.016) (Kato ET et al, Circulation 2019;139:2528–36). 
 
EMPRISE Study / Interim Analysis: Compared With 
Sitagliptin, the Initiation of Empagliflozin Was 
Associated With a Decreased Risk of Hospitalization 
for Heart Failure (HHF) Among Patients With Type 2 
Diabetes as Treated in Routine Care, With and 
Without a History of Cardiovascular (CV) Disease  
Among propensity-score matched 16,443 patient pairs 
started on empagliflozin or sitagliptin (mean age 59 years, 
54% males, ~25% with CV disease), compared with 
sitagliptin, the initiation of empagliflozin decreased the 
risk of HHF-specific by 50% (HR, 0.50), and the risk of 
HHF-broad by 49% (HR, 0.51), over a mean of 5.3 
months. The results were consistent in patients with and 
without baseline CV disease, and for empagliflozin at both 
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the 10- and 25-mg daily doses; analyses comparing empa-
gliflozin vs the dipeptidyl peptidase-4 inhibitor (DPP-4i) 
class, and comparing sodium-glucose cotransporter-2 
inhibitor vs DPP-4i classes also produced consistent 
findings (Patorno E et al, Circulation 2019;139:2822-30).  
 
Transcatheter Valve Therapy Registry: Inverse 
Volume-Mortality Association for Transfemoral TAVI 
Procedures / Higher and More Variable Mortality at 30 
Days at Hospitals With a Low Procedural Volume 
Than at Hospitals With a High Procedural Volume 
Among 96,256 transfemoral TAVI procedures, there 
was a significant inverse association between annualized 
volume of transfemoral TAVI procedures and mortality. 
Adjusted 30-day mortality was higher and more variable at 
hospitals in the lowest-volume quartile (3.19%) than at 
hospitals in the highest-volume quartile (2.66%) (odds 
ratio-OR, 1.21; P=0.02). The difference in adjusted 
mortality between a mean annualized volume of 27 
procedures in the lowest-volume quartile and 143 
procedures in the highest-volume quartile was a relative 
reduction of 19.45%. After the exclusion of the first 1 year 
of TAVI procedures at each hospital, 30-day mortality 
remained higher in the lowest-volume quartile than in the 
highest-volume quartile (3.10% vs 2.61%; OR, 1.19) 
(Vemulapalli S et al, N Engl J Med 2019; 380:2541-50). 
 
WRAP-IT: Adjunctive Use of an Antibacterial 
Envelope Resulted in a Significantly Lower Incidence 
of Major CIED Infections Than Standard-Of-Care 
Infection-Prevention Strategies Alone, Without a 
Higher Incidence of Complications 
Among 6983 patients undergoing implantation of a 
cardiac implantable electronic device (CIED) randomized 
to the envelope (n=3495) or to the control group (n=3488), 
over 20.7±8.5 months, infection occurred in 25 patients in 
the envelope group and 42 patients in the control group 
(12-month Kaplan–Meier estimated event rate, 0.7% and 
1.2%, respectively; hazard ratio-HR, 0.60; P=0.04). The 
safety end point (complications) occurred in 201 patients 
in the envelope group and 236 patients in the control group 
(12-month Kaplan–Meier estimated event rate, 6% and 
6.9%, respectively; HR, 0.87; P<0.001 for noninferiority). 
Major CIED-related infections through the entire follow-
up period occurred in 32 patients in the envelope group and 
51 patients in the control group (HR, 0.63). (Tarakji KG et 
al, N Engl J Med 2019; 380:1895-1905).  
 
RE-SPECT ESUS: In Patients With a Recent Embolic 
Stroke of Undetermined Source, Dabigatran Was Not 
Superior to Aspirin in Preventing Recurrent Stroke  
Among 5390 patients with an embolic stroke of 
undetermined source randomized to dabigatran (2695 
patients) or aspirin (2695 patients), over a median of 19 
months, recurrent strokes occurred in 177 patients (6.6%) 
in the dabigatran group (4.1% per year) and in 207 patients 
(7.7%) in the aspirin group (4.8% per year) (hazard ratio-
HR, 0.85; P=0.10). Ischemic strokes occurred in 172 
patients (4.0% per year) vs 203 patients (4.7% per year) 
(HR, 0.84), major bleeding in 77 patients (1.7% per year) 
vs 64 patients (1.4% per year) (HR, 1.19), and clinically 
relevant nonmajor bleeding in 70 patients (1.6% per year) 
vs 41 patients (0.9% per year) (Diener HC et al, N Engl J 
Med 2019; 380:1906-17).  
 
Evolut Low Risk Trial: In Patients With Severe 
Aortic Stenosis (AS) at Low Surgical Risk, TAVI 
with a Self-Expanding Bioprosthesis Was 
Noninferior to Surgery With Respect to Death or 
Disabling Stroke at 2 Years 
Among 1403 low-risk patients (mean age 74 
years) with severe AS randomized to TAVI or 
surgery, the 2-year incidence of the primary end point 
(death or stroke) was 5.3% in the TAVI group and 
6.7% in the surgery group. At 30 days, TAVI patients 
had a lower incidence of stroke (0.5% vs 1.7%), 
bleeding (2.4% vs 7.5%), acute kidney injury (0.9% 
vs 2.8%), and atrial fibrillation (7.7% vs 35.4%) and 
a higher incidence of moderate/severe aortic 
regurgitation (3.5% vs 0.5%) and pacemaker 
implantation (17.4% vs 6.1%). At 1 year, TAVI 
patients had lower aortic-valve gradients (8.6 vs 11.2 
mmHg) and larger effective orifice areas (2.3 vs 2 
cm2) (Popma JJ et al, N Engl J Med 2019;380:1706-15).  
 
Ultra-Short-Term Combined Treatment With I.V. 
Iron, s.c. Erythropoietin Alpha, Vitamin B12, and p.o. 
Folic Acid Reduced RBC and Total Allogeneic Blood 
Product Transfusions in Patients With Preoperative 
Anemia or Isolated Iron Deficiency Undergoing 
Elective Cardiac Surgery 
Patients with anemia undergoing elective cardiac 
surgery (n=253; Hb <12 g/dL in women and Hb <13 g/dl 
in men) or isolated iron deficiency (n=252; ferritin <100 
mcg/L, no anemia) were randomly assigned (1:1) to 
receive either placebo (n=501) or combination treatment 
(n=505) with a slow infusion of 20 mg/kg ferric 
carboxymaltose, 40 000 U sc erythropoietin alpha, 1 mg sc 
vitamin B12, and 5 mg oral folic acid or placebo on the day 
before surgery. The combination treatment significantly 
reduced RBC transfusions from a median of 1 unit in the 
placebo group to 0 units in the treatment group (odds ratio 
0.70 for each threshold of number of RBC transfusions, 
p=0.036) and until postoperative day 90 (p=0.018). 
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Despite fewer RBC units transfused, patients in the 
treatment group had a higher Hb concentration, higher 
reticulocyte count, and a higher reticulocyte Hb content 
during the first 7 days (p≤0·001). Combined allogeneic 
transfusions were less in the treatment group (median 0 vs 
1 the placebo group (during the first 7 days, p=0·038; and 
until postoperative day 90, p=0·019). 73 (30%) serious 
adverse events were reported in the treatment group vs 79 
(33%) in the placebo group (Spahn DR et al, Lancet 
2019;393:2201-12).  
 
Coronary Stent Trialists: The Performance of New-
Generation DES in the First Year After Implantation 
Means That BMS Should no Longer be Considered the 
Gold Standard for Safety / Further Development of 
DES Technology Should Target Improvements in 
Clinical Outcomes Beyond 1 Year 
A meta-analysis of 20 RCTs comparing new-
generation DES or BMS among 26,616 patients 
undergoing PCI, indicated that over a mean of 3.2 years, 
the risk of the primary outcome (death or MI) was reduced 
in DES recipients compared with BMS recipients (HR 
0.84, p<0.001) owing to a reduced risk of MI (0.79, 
p<0.001) and a possible slight but non-significant cardiac 
mortality benefit (0.89, p=0.075). All-cause death was 
unaffected (HR with DES 0·96, p=0.358), but risk was 
lowered for definite stent thrombosis (0.63, p<0·001) and 
target-vessel revascularisation (0.55, p<0.001). A time-
dependent treatment effect was seen, with DES being 
associated with lower risk of the primary outcome than 
BMS up to 1 year after placement. While the effect was 
maintained in the longer term, there was no further 
divergence from BMS after 1 year (Piccolo R et al, Lancet 
2019; 393:2503-10).  
 
Spontaneous Coronary Artery Dissection (SCAD) 
Mainly Affects Women and Presents With MI / Despite 
Conservative Treatment for the Majority of Patients, 
Survival was Good but with Significant Cardiovascular 
Complications Occurring Within 30 Days  
Among 750 patients with non-atherosclerotic SCAD 
presenting acutely (age 51.8 ± 10.2 years, 88.5% women - 
55% postmenopausal, 87.7% Caucasian, and 33.9% with 
no cardiac risk factors), emotional stress was reported in 
50.3%, and physical stress in 28.9% (9.8% lifting >50 
pounds). Predisposing conditions included fibromuscular 
dysplasia 31.1% (45.2% had no/incomplete screening), 
systemic inflammatory diseases 4.7%, peripartum 4.5%, 
and connective tissue disorders 3.6%. Most were treated 
conservatively (84.3%), but 14.1% underwent PCI and 
0.7% coronary artery bypass surgery. In-hospital major 
adverse event rate was 8.8% with a higher rate (20.6% vs 
8.2%; p=0.023) in peripartum SCAD patients. Overall 30-
day MACE was 8.8%. Peripartum SCAD and connective 
tissue disease were independent predictors of 30-day 
MACE (Saw J et al, Eur Heart J 2019;40: 1188–97). 
 
In Routine Clinical Care, AF Ablation Was Associated 
With a Reduction in the Primary Composite Endpoint 
of All-Cause Mortality, Stroke, Major Bleeding, and 
Cardiac Arrest  
A US database identified 183,760 patients with AF 
treated with ablation or medical therapy. Propensity score 
weighting was used to balance patients treated with 
ablation (N = 12,032) or medical therapy (N = 171,728). 
Ablation was associated with a reduction in the composite 
endpoint of all-cause mortality, stroke, major bleeding, and 
cardiac arrest (hazard ratio - HR 0.75; P < 0.001). The 
majority of patients (73.8%) were potentially trial eligible; 
among whom the risk reduction associated with ablation 
was greatest (HR 0.70; P < 0.001). Among the 3.8% of 
patients who failed to meet the inclusion criterion, i.e. 
patients under 65 years without stroke risk factors, the 
event rates were low and there was no significant 
relationship with ablation (HR 0.67; P = 0.35). Among the 
22.4% patients who met at least one of the trial exclusion 
criteria, there was a lesser but statistically significant 
reduction associated with ablation (HR 0.85; P = 0.01) 
(Noseworthy PA et al, Eur Heart J 2019;40: 1257–64). 
 
Age is an Important Driver for Ischemic Stroke Risk in 
AF / Age Thresholds for Use of NOACs Were Different 
for AF Patients Having Different Single Risk Factors 
Beyond Sex Despite the Same CHA2DS2-Vasc Score 
Point (1 for Males and 2 For Females), i.e. 35 Years for 
Heart Failure, 50 Years for Hypertension or Diabetes, 
and 55 Years for Vascular Diseases 
In a study cohort of 31,039 and 39,020 AF patients 
who did not have any or had only one risk factor 
comorbidity of the CHA2DS2-VASc score except for age 
and sex, the tipping point for the use of NOACs was set at 
a stroke risk of 0.9%/year. The overall risk of ischemic 
stroke using the conventional way was overestimated 
compared to the dynamic or ideal assessment with the 
incidence rate ratio of 1.24 for patients with hypertension, 
1.20 for heart failure, 1.37 for diabetes mellitus, and 1.38 
for vascular diseases; all P-values <0.01. With heart 
failure, the tipping point (age 35 years) of NOACs was 
similar, irrespective of methods used for stroke risk 
assessment. According to the results of ideal assessment, 
the age thresholds for the use of NOACs for patients with 
hypertension, diabetes mellitus, and vascular diseases 
were 50 years, 50 years, and 55 years, respectively (Chao 
T-F et al, Eur Heart J 2019;40: 1504–14).  
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Overall Risk of Infection was Low in Pacemaker (PM) 
Implantations But Considerably Higher in CRT 
Systems and After Reinterventions  
In the Danish Pacemaker (PM) and ICD Register, 
including 97,750 patients, 1827 device-related infections 
(DRI) causing device removals were identified with an 
incidence during device lifetime of 1.19% for PM, 1.91% 
for ICD, 2.18% for CRT-P, and 3.35% for CRT-D. 
Incidence rates in de novo implantations were 2.04/1000 
DY for PM, 3.84 for ICD, 4.38 for CRT-P, and 6.76 for 
CRT-D. Implantation of complex devices (ICD and CRT), 
reoperations, prior DRI, male sex, and younger age as 
significantly associated with higher DRI risk (Olsen T et 
al, Eur Heart J 2019; 40: 1862–9).  
 
Proton Pump Inhibitor Therapy is Used Less Than 
Suggested by Guidelines in Patients Treated With 
DAPT Following MI and Was Generally Associated 
With Reduced Risk of GI Bleeding  
Among 46,301 patients on DAPT after MI, only 35% 
of patients at higher risk of GI bleeding received 
recommended treatment with a PPI based on the guideline 
criteria. The 1-year risk of GI bleeding was 1% and 1.7% 
for high-risk patients. Overall PPI compared with no 
therapy, was associated with a risk ratio for GI bleeding of 
0.62 corresponding to an absolute risk difference of 0.44%. 
PPI therapy was associated with a similar absolute risk 
difference (0.47%) for high-risk patients (Sehested TSG et 
al, Eur Heart J 2019;40: 1963-70).  
 
Vernakalant was Effective in Converting Recent Onset 
AF, Did not Require Monitoring in the Cardiac Care 
Unit, was Well Tolerated and May Effectively Replace 
Ibutilide in the Routine Care of These Patients 
Vernakalant, a novel antiarrhythmic agent approved 
for conversion of recent-onset atrial fibrillation (AF), 
heralded as safer agent compared to ibutilide, was used in 
23 consecutive patients (13 men; age 63±12 years) with 
recent-onset AF of 42±64 h duration, with ventricular rate 
of 115±20 bpm. Vernakalant was given as a first infusion 
at 3 mg/kg given over 10 min, followed by a second 
infusion at 2 mg/kg at 15 min later if AF was not 
terminated. Patients received the drug in the cardiology 
ward with bedside-monitoring alone. Conversion of AF 
was achieved in 15 (65%) patients within 25±31 min. A 
higher (85.7%) conversion rate was observed in patients 
without underlying structural heart disease (p=0.035). The 
study included 9 (39%) patients who failed conversion 
with amiodarone, and 5 (55.6%) responded to vernakalant. 
Conversion was independent of left atrial size, arrhythmia 
duration, gender or type of prior drug intake. Patients 
tolerated the medication well with only minor side-effects 
in 7 (Manolis AS et al, Hellenic J Cardiol 2019;60:54-56) 
 
Important Review and Other Articles  
 
● Ablation of ventricular arrhythmias (Shivkumar K et al, N 
Engl J Med 2019; 380:1555-1564)  
 
● Obstructive sleep apnea (Veasey SC et al, N Engl J Med 2019; 
380:1442-1449) 
 
● Transthyretin amyloid cardiomyopathy (Ruberg FL et al, J Am 
Coll Cardiol 2019;73:2872-91) 
 
● Atrial functional mitral regurgitation (Deferm S et al, J Am 
Coll Cardiol 2019;73:2465-76) 
 
● Depression in patients with cardiovascular disease (Jha MK et 
al, J Am Coll Cardiol 2019;73:1827-45)  
 
● Type 2 MI (Sandoval Y et al, J Am Coll Cardiol 
2019;73:1846-60)  
 
● Renal denervation update (Kiuchi MG et al, J Am Coll 
Cardiol 2019;73:3006-17) 
 
● Right ventricle (Sanz J et al, J Am Coll Cardiol 2019;73: 
1463-82) 
 
● Intestinal microbiota in CV health and disease (Tang WHW 
et al, J Am Coll Cardiol 2019;73:2089-105) 
 
● Arrhythmia-induced cardiomyopathy (Huizar JF et al, J Am 
Coll Cardiol 2019;73:2328-44) 
 
● Cardiorenal syndrome / AHA Scientific statement 
(Rangaswami J et al Circulation 2019;139:e840–78) 
 
● Sudden death in HFpEF (Manolis AS et al, Heart Fail Rev 
2019 May 30. doi: 10.1007/s10741-019-09804-2) 
 
● CV effects of alcohol (Manolis TA et al, Alcohol 2019 
May;76:117-129) 
 
● MINOCA, AHA Scientific Statement (Tamis-Holland J et al, 
Circulation 2019;139:e891–e908)  
 
● Aortic stenosis and small aortic annulus (Freitas-Ferraz AB 
et al, Circulation. 2019;139:2685–2702) 
 
● American Guidelines on Cholesterol (Grundy SM et al, 
Circulation 2019;139:e1082–e1143) 
 
● Thyroid and CVD (Cappola AR et al, Circulation 
2019;139:2892–2909) 
 
● Subclinical thyroid dysfunction and CV consequences 
(Manolis AA et al, Trends Cardiovasc Med 2019 Mar 5. pii: 
S1050-1738(19)30029-5. doi: 10.1016/j.tcm.2019.02.011) 
 
● The rise and fall of aspirin in the primary prevention of CV 
disease (Raber I et al, Lancet 2019; 393: 2155–67) 
 
● HFpEF, AF and senile amyloidosis (van den Berg MP et al, 
Eur Heart J 2019;40) 
 
● Management of left main disease (Fajadet J et al, Eur Heart J 
2019;40: 1454–66) 
 
 
